Adaptive Biotechnologies Corporation

NasdaqGS:ADPT Aktierapport

Börsvärde: US$2.1b

Adaptive Biotechnologies Tidigare resultatutveckling

Tidigare kriterier kontrolleras 0/6

Adaptive Biotechnologies har ökat intäkterna med en genomsnittlig årlig takt på 8.1%, medan Life Sciences -branschen såg intäkterna minskande på 4.6% årligen. Intäkterna har varit växande med en genomsnittlig takt på 12.4% per år.

Viktig information

8.13%

Tillväxttakt i vinsten

9.81%

Tillväxttakt för EPS

Life Sciences Tillväxt i branschen21.51%
Intäkternas tillväxttakt12.43%
Avkastning på eget kapital-26.43%
Nettomarginal-21.48%
Nästa resultatuppdatering05 May 2026

Senaste uppdateringar av tidigare prestationer

Recent updates

ADPT: MRD Revenue Outlook And Refreshed Models Will Support Future Cash Flows

Narrative Update on Adaptive Biotechnologies The consensus analyst price target for Adaptive Biotechnologies has moved up by $1, reflecting updated analyst models that incorporate adjusted discount rates, refreshed revenue growth and profit margin assumptions, and a revised, still very large forward P/E framework. Analyst Commentary Recent Street research on Adaptive Biotechnologies centers on modestly higher price targets, with several bullish analysts revising their models at roughly the same time.

ADPT: MRD 2026 Outlook And Discount Assumptions Will Support Future Upside Potential

Analysts have raised their price targets on Adaptive Biotechnologies by about $1, reflecting updated views on discount rates, growth, margins, and future P/E assumptions. These changes keep the stock's fair value estimate effectively unchanged at around $21.

ADPT: MRD Outlook And Pfizer Agreements Will Support Future Cash Flows

Analysts have inched their average price targets on Adaptive Biotechnologies higher, often by about $1 increments. These changes reflect updated views that modestly adjust revenue growth, profit margin and future P/E assumptions while keeping the fair value estimate near $22.

ADPT: MRD And Pfizer Agreements Will Support Future Cash Flow Upside

The analyst price target for Adaptive Biotechnologies has shifted from $21.00 to $22.00. Analysts point to updated assumptions around growth, profitability, and long-term P/E expectations following a series of recent target increases across the Street.

ADPT: Pfizer Agreements And MRD Progress Will Support Future Upside Potential

Analysts have nudged their average price target for Adaptive Biotechnologies higher by about $1, reflecting updated fair value assumptions and slightly revised views on growth, margins and future P/E, in line with recent target increases from several research firms. Analyst Commentary Recent research updates cluster around modest target increases and a generally supportive view of Adaptive Biotechnologies, with most of the focus on refreshed fair value work rather than sweeping changes to the thesis.

ADPT: Sector Tailwinds And Pfizer Partnerships Will Support Measured Future Upside

Analysts have nudged their price targets on Adaptive Biotechnologies slightly higher, with Street research pointing to target increases such as TD Cowen moving to $20 from $19. This contributes to a modest lift in our fair value estimate from $20.00 to about $20.14 as they highlight solid expected sector results and fundamentals.

ADPT: Sector Tailwinds And Cancer Testing Leadership Will Support Future Upside

Narrative Update: Adaptive Biotechnologies The analyst price target for Adaptive Biotechnologies has moved from $19 to $20, reflecting updated views that incorporate recent Q4 preview work on diagnostics peers, expectations for solid sector results and 2026 outlooks, and the company’s latest Q3 report. Analyst Commentary Recent Street research around Adaptive Biotechnologies has focused on updated price targets that reflect fresh sector work and the company’s latest Q3 report.

ADPT: MRD Platform And Pfizer Agreements Will Support Long-Term Cash Flow Upside

Analysts have lifted their price target on Adaptive Biotechnologies to $16 from $11, citing the recent Q3 report as the key driver behind this updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the new US$16 price target, up from US$11, as a sign that expectations for execution and risk reward have shifted in a more constructive direction after the recent Q3 report.

Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle

Dec 26

ADPT: MRD Leadership Will Drive Long-Term Cash Flow Upside

Analysts have raised their fair value estimate for Adaptive Biotechnologies from approximately $15 to $21 per share. They cite higher long term profit margin expectations and confidence in the company’s leadership in minimal residual disease cancer testing, even with moderating revenue growth assumptions and a higher discount rate.

ADPT: Future Revenue Will Be Sustained By Leadership In Cancer Testing

Analysts have raised their fair value estimate for Adaptive Biotechnologies to $19.57 from $19.14. They cite increased confidence in the company's sustained revenue growth and leadership position in cancer testing.

ADPT: Future Revenue Will Be Driven By Market Expansion In Blood Cancer Testing

Analysts have raised their price target for Adaptive Biotechnologies by $2.00 to $19.14, citing the company's leadership in minimal residual disease testing, as well as expectations for sustained revenue growth and improved margins. Analyst Commentary Recent analyst discussions reveal diverse perspectives on Adaptive Biotechnologies' position in the market and future prospects.

ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks

Analysts have increased their price target for Adaptive Biotechnologies from $16.00 to $17.14 per share. They cite continuing leadership in cancer testing and expectations for robust revenue growth, driven by market expansion and operational improvements.

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors

Oct 16
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Analysts have increased their price target for Adaptive Biotechnologies from $14 to approximately $14.86 per share. They cite ongoing revenue growth momentum and strengthening leadership in the cancer diagnostics market as key drivers of the upward revision.

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

Sep 24
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce

Aug 29
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29. What's in the News Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher

May 31
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?

May 07
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?

Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge

Apr 10
Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge
User avatar

ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines

Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth.

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher

Feb 14
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher

Adaptive Biotechnologies: Making Some Progress

Nov 26

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Nov 26
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Fördelning av intäkter och kostnader

Hur Adaptive Biotechnologies tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.

Resultat- och intäktshistorik

NasdaqGS:ADPT Intäkter, kostnader och resultat (USD Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
31 Dec 25277-5916794
30 Sep 25253-801630
30 Jun 25205-1211590
31 Mar 25190-1421560
31 Dec 24179-159158103
30 Sep 24177-1951610
30 Jun 24169-2131630
31 Mar 24175-2151710
31 Dec 23170-225173122
30 Sep 23180-1961760
30 Jun 23190-1911780
31 Mar 23184-1951770
31 Dec 22185-2001840
30 Sep 22168-2211880
30 Jun 22160-2321910
31 Mar 22155-2291850
31 Dec 21154-2071700
30 Sep 21147-1901520
30 Jun 21133-1711330
31 Mar 21116-1551210
31 Dec 2098-1461110
30 Sep 2092-1221000
30 Jun 2092-99910
31 Mar 2093-82800
31 Dec 1985-70690
30 Sep 1978-62630
30 Jun 1969-56560
31 Mar 1959-53500
31 Dec 1856-46450
31 Dec 1738-43330

Kvalitetsintäkter: ADPT är för närvarande olönsam.

Växande vinstmarginal: ADPT är för närvarande olönsam.

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Resultatutveckling: ADPT är olönsam, men har minskat förlusterna under de senaste 5 åren med en hastighet av 8.1% per år.

Accelererande tillväxt: Det går inte att jämföra ADPT s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt

Resultat vs industri: ADPT är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Life Sciences branschen ( 2.5% ).

Avkastning på eget kapital

Hög ROE: ADPT har en negativ avkastning på eget kapital ( -26.43% ), eftersom det för närvarande är olönsamt.

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/04/30 22:04
Aktiekurs vid dagens slut2026/04/30 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Adaptive Biotechnologies Corporation bevakas av 13 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Derik de BruinBofA Global Research
Mark MassaroBTIG
William BonelloCraig-Hallum Capital Group LLC